Partner Phase 1 Phase 2 Majority / Fully-owned pipeline Botensilimab +/- Balstilimab Fc-enhanced CTLA-4 +/- PD-1 Non-MSI-H-colorectal cancer More Info Botensilimab +/- Balstilimab Fc-enhanced CTLA-4 +/- PD-1 PD-1 r/r melanoma ...
These partnerships generate capital to further support our pipeline development, and many offer optionality for future participation in development and commercialization. Learn more about our partnerships Who we are We have brought together top talent and expertise to advance our mission, building a...
Agenus (NASDAQ:AGEN) is an immuno-oncology (IO) company with a deep and diversified pipeline, a technology for novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing. Agenus believes that these fully integrated capabilities are the ...
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive ...
As someone who has spent a significant portion of my career in healthcare advertising and strategic advising of CEOs across the healthcare industry, I'm excited to bring my experience to Agenus. The opportunity to help elevate the awareness of our innovative pipeline and to communicate the signif...
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeut...
Agenus Inc., a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 will be presented in an oral presentation at the upcoming AACR Meeting, to be held Ap
21 Jun 2023 Phase-II clinical trials in Squamous cell cancer (Parenteral) (Agenus pipeline, June 2023) 02 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023) 02 ...
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeut...
Agenus (AGEN) Q1 2023 Earnings Call Transcript AGEN earnings call for the period ending March 31, 2023. Motley Fool Transcribing | May 9, 2023 Related Stocks OTC: DMTK DermTech Market Cap $705MM Current Price $0.01 NASDAQ: BLUE Bluebird Bio ...